The firm said directors appointed included: Chris Bunka, John Docherty, Nicholas Baxter and Ted McKechnie. The firm noted Davidson & Company LLP has been appointed as auditor.
The firm noted shareholders also approved executive compensation.
Lexaria has developed and out-licenses its delivery technology, which promotes healthier ingestion methods and lower overall dosing. Its DehydraTECH technology is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time. The firm acquired its technology in 2014.
Lexaria's technology provides boosts in intestinal absorption rates and more rapid bloodstream delivery for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs, nicotine and other molecules.
The firm has patents pending in more than 40 countries.
Shares of Lexaria Bioscience were at C$1.10 on Friday.
Contact Katie Lewis at [email protected]